DiaMedica Therapeutics Inc. (DMAC)

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on September 18, 2025, it granted stock options to purchase an aggregate of 490,000 shares of DiaMedica's common stock to five newly hired non-executive employees whose employment commenced in August and September 2025. The stock options were approved.

Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.

DiaMedica Therapeutics, Inc. (DMAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DMAC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Positive interim phase 1a data for DM199 in preeclampsia establishes proof-of-concept and supports expansion to phase 1b and fetal growth restriction studies. DM199's mechanism targets key factors in preeclampsia, offering a potential best-in-class, disease-modifying therapy in a large, underserved market. Strong cash position of $60.1 million extends runway into 2H 2027, supporting ongoing and expanded clinical development.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical Officer Scott Kellen - CFO & Corporate Secretary Conference Call Participants Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2025. Management will host a conference call Wednesday, August 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 2.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial res.

Insider buying has been slow this past month, as buy windows close as the new earnings-reporting season gets underway.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approximately 8.6 million common shares at a purchase price of $3.50 per share. After deducting estimated offering expenses, t.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced definitive agreements for a $30.1 million private placement of common shares led by current investors. No placement agent was engaged for this transaction. Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 8,606,.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced positive interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia. The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase, reinforcing the therapeutic potential of DM199. DM199, rinvecalinase alfa, is a recombinant form of the KLK1 protein expected to influence blood pressure regula.